A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Unilateral Intratympanic PIPE-505 in Subjects With Sensorineural Hearing Loss Associated With Speech-in-Noise Impairment

This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.

开始日期2020-10-15

申办/合作机构

Contineum Therapeutics, Inc.初创企业

100 项与 PIPE-505 相关的临床结果

登录后查看更多信息

100 项与 PIPE-505 相关的转化医学

登录后查看更多信息

100 项与 PIPE-505 相关的专利（医药）

登录后查看更多信息

项与 PIPE-505 相关的新闻（医药）

2023-12-15

·FiercePharma

New year, new name as Pipeline, Novozymes and Chr. Hansen rebranded to reflect new focus

The companies are the latest in a series of biotechs to ditch their old names. With a new year on the horizon, a clutch of companies have decided on new names for 2024. Pipeline Therapeutics has become Contineum Therapeutics, while Novozymes and Chr. Hansen have picked Novonesis as their new shared identity. Companies rebrand for a wide range of reasons. Some are trying to distance themselves from a troubled past, others simply outgrow their original names as they expand beyond their original focus. A third set of companies need to find a new name when they merge, either by mashing together their existing brands or by creating a new identity that reflects their ambitions for the combined organization. Pipeline framed its rebrand as a product of an expanded focus. The biotech grew out of a deal between Roche and VC shop Versant Ventures. When Roche bought one program, Versant set up a successor, Pipeline, to develop neuro-regenerative therapies. Five years later, Pipeline has expanded its focus to cover oral small-molecule therapies for neuroscience, inflammation and immunology indications. The biotech picked Contineum as its new name in the belief it “represents its continuous dedication to the pursuit of scientific discovery and cutting-edge solutions designed to benefit patients.” In 2021, the biotech raised an $80 million series C round to fund work on PIPE-505 in sensorineural hearing loss and PIPE-307 in multiple sclerosis. Later, PIPE-505 quietly disappeared from the pipeline. The current pipeline is headed up by PIPE-791, which is in development in indications including idiopathic pulmonary fibrosis. The circumstances of the Novozymes-Chr. Hansen rebrand are different. One year ago, Novozymes agreed to pay $12.3 billion to acquire the biotech ingredients supplier. This week, the parties received European Commission clearance to close the deal and quickly followed up with details of a new name. According to the companies, the “name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. The new name will be implemented “gradually” once the merger closes next year.

并购

2021-11-10

·BioSpace

Pipeline Therapeutics to Participate in the Stifel 2021 Virtual Healthcare and Jefferies London Healthcare Conferences

Nov. 10, 2021 13:00 UTC SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that the company will participate in two upcoming investor conferences. On November 17, 2021, the Company will participate in the Stifel 2021 Virtual Healthcare Conference, and on November 18, 2021, the Company will participate in the Jefferies London Healthcare Conference. About Pipeline Therapeutics Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, including remyelination, synaptogenesis and axonal repair. Pipeline has two product candidates in clinical development: PIPE-307, targeting remyelination to treat multiple sclerosis, which recently completed a Phase 1 healthy volunteer study, and PIPE-505, targeting sensorineural hearing loss associated with speech-in-noise disability, which recently completed a Phase 1/2a study. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit .

First in Class小分子药物

2021-02-11

·BioSpace

Pipeline Therapeutics Completes $80 Million Series C Financing

SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the closing of an $80 million Series C financing. The oversubscribed financing was led by a healthcare-focused new investor, with participation by other new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, and an undisclosed leading global investment fund. All of the company’s existing shareholders, including founding investor Versant Ventures, Sectoral Asset Management and Cleva Pharma (a Brace Pharma affiliate), participated in the round. Pipeline Therapeutics plans to use the proceeds to advance its development candidates PIPE-505, in patients with sensorineural hearing loss, and PIPE-307, in patients with multiple sclerosis. Proceeds will also be used to advance additional therapeutic candidates and for general corporate purposes. “We are delighted to welcome the new investors in our Series C round, and are grateful to our existing shareholders for their continued support,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “We are proud to have this significant support for our mission of developing first- and best-in-class neuroregenerative product candidates for unserved and underserved neurological indications.” Pipeline Therapeutics is currently running a Phase 1/2a clinical trial to treat sensorineural hearing loss. In addition, the company recently initiated a Phase 1 clinical trial in healthy volunteers for PIPE-307. About Pipeline Therapeutics Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company has also initiated a Phase 1 healthy volunteer study for its second clinical program, PIPE-307, targeting multiple sclerosis. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit .

First in Class小分子药物

100 项与 PIPE-505 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经性听力损失	临床2期	-	Contineum Therapeutics, Inc.初创企业	-
言语障碍	临床前	美国	Contineum Therapeutics, Inc.初创企业	2020-10-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04462198 (CTgov)	临床1/2期	言语障碍 \| 神经性听力损失	28	PIPE-505 (PIPE-505)	窪鑰簾範簾顧鏇艱衊夢(壓憲簾醖醖膚獵觸築網) = 鹽製顧鑰構顧襯鬱艱夢衊窪齋壓範膚遞憲願築 (鬱鏇鑰膚糧廠繭憲鬱構, 蓋繭襯餘醖蓋艱夢窪衊 ~ 顧鹹夢餘築構繭繭願醖) 更多	-	2025-03-04
				Placebo (Placebo)	窪鑰簾範簾顧鏇艱衊夢(壓憲簾醖醖膚獵觸築網) = 遞繭簾壓糧鹽壓襯窪淵衊窪齋壓範膚遞憲願築 (鬱鏇鑰膚糧廠繭憲鬱構, 遞廠築積範蓋淵構窪構 ~ 簾構鹹繭鏇積鏇鹽淵構) 更多